国际标准期刊号: 2573-4555

传统医学和临床自然疗法

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 参考搜索
  • 研究期刊索引目录 (DRJI)
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Chinese Drug can be Used in Combination with Monoclonal Antibody Medicines to Reduce the Side Effects of COVID- 19

Robert Wallace

The mortality rate of the recent global epidemic corona virus disease 2019(COVID- 19) is presently as high as 7%.The SARS- CoV- 2 contagion is the malefactor behind COVID- 19. SARS- CoV- 2 is an enveloped single- stranded RNA contagion; the genome encodes four types of the structural proteins S protein, E protein (envelope protein),M protein (matrix protein) and N protein (nucleocapsid protein). In COVID- 19, monoclonal antibodies have played a significant part in opinion and treatment. This composition compactly introduced the development of monoclonal antibodies targeting on S protein and N protein, which represents the main direction of monoclonal antibody medicines used in the opinion and treatment of COVID- 19. Meanwhile, the traditional Chinese drug also plays important part in the fight against COVID- 19 by regulating human immunity. The composition introduced the use of traditional Chinese drug in fighting against COVID- 19.